Considerations for the genotoxicity assessment of middle size peptide drugs containing non-canonical amino acid residues

Genes and Environment - Tập 45 Số 1
Masayuki Mishima1, Keiichi Sugiyama2
1Translational Research Division, Chugai Pharmaceutical Co., Ltd, Yokohama, Japan
2Division of Genetics and Mutagenesis, National Institute of Health Sciences, Kawasaki, Japan

Tóm tắt

Abstract Background Middle size peptides (MSPs) have emerged as a promising new pharmaceutical modality. We are seeking the best way to assess the non-clinical safety of MSPs. Consideration The requirements for assessing the genotoxicity of pharmaceuticals differ between small molecule drugs and biotherapeutics. Genotoxicity tests are necessary for small molecule drugs but not for biotherapeutics. MSPs, however, share similarities with both small molecule drugs and biotherapeutics. Here, we describe important points to consider in assessing the genotoxicity of MSP drugs. The current standard of genotoxicity assessment for small molecules may not be entirely appropriate for MSP drugs. MSP drugs need genotoxicity assessment mostly according to the current standard of small molecule drugs. Conclusion We propose a few modifications to the standard test battery of genotoxicity tests, specifically, the inclusion of an in vitro gene mutation test using mammalian cells, and exclusion of (Q)SAR assessment on MSP-related impurities.

Từ khóa


Tài liệu tham khảo

Goto Y, Katoh T, Suga H. Flexizymes for genetic code reprogramming. Nat Protoc. 2011;6(6):779–90.

Matsumoto Y, Sawamura J, Murata Y, Nishikata T, Yazaki R, Ohshima T. Amino Acid Schiff Base Bearing Benzophenone Imine As a Platform for Highly Congested Unnatural α-Amino Acid Synthesis. J Am Chem Soc. 2020;142(18):8498–505.

Wang W, Khojasteh SC, Su D. Biosynthetic strategies for macrocyclic peptides. Molecules. 2021;26(11):3338.

Inokuma T. Synthesis of Non-canonical Amino Acids and Peptide Containing Them for Establishment of the Template for Drug Discovery. Chem Pharm Bull (Tokyo). 2021;69(4):303–13.

Fuse S, Otake Y, Nakamura H. Peptide Synthesis Utilizing Micro-flow Technology. Chem Asiam J. 2018;13(24):3818–32.

Du Y, Li L, Zheng Y, Liu J, Gong J, Qiu Z, et al. Incorporation of Non-Canonical Amino Acids into Antimicrobial Peptides: Advances, Challenges, and Perspectives. Appl Environ Microbiol. 2022;88(23):e0161722.

Sakai K, Sugano-Nakamura N, Mihara E, Rojas-Chaverra NM, Watanabe S, Sato H, et al. Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions. Nat Biomed Eng. 2023;7(2):164–76.

Mishiro K, Ueno T, Wakabayashi H, Fukui M, Kinuya S, Ogawa K. Synthesis and evaluation of a deltic guanidinium analogue of a cyclic RGD peptide. Org Biomol Chem. 2023;21(9):1937–41.

Kobayashi M, Fujita K, Matsuda K, Wakimoto T. Streamlined Chemoenzymatic Synthesis of Cyclic Peptides by Non-ribosomal Peptide Cyclases. J Am Chem Soc. 2023;145(6):3270–5.

Takayama K, Hitachi K, Okamoto H, Saitoh M, Odagiri M, Ohfusa R, Shimada T, Taguchi A, Taniguchi A, Tsuchida K, Hayashi Y. Development of Myostatin Inhibitory d-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice. ACS Med Chem Lett. 2022;13(3):492–8.

Stebbings R, Poole S, Thorpe R. Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol. 2009;20(6):673–7.

S6(R1) I. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. 2011.

Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66(4):807–15.

Takeuchi K, Misaki I, Tokunaga Y, Fujisaki M, Kamoshida H, Takizawa T, et al. Conformational Plasticity of Cyclic Ras-Inhibitor Peptides Defines Cell Permeabilization Activity. Angew Chem Int Ed Engl. 2021;60(12):6567–72.

Zhang Q, Liu N, Wang J, Liu Y, Wang K, Zhang J, et al. The recent advance of cell-penetrating and tumor-targeting peptides as drug delivery systems based on tumor microenvironment. Mol Pharm. 2023;20(2):789–809.

Choudhary AK, Pretorius E. Revisiting the safety of aspartame. Nutr Rev. 2017;75(9):718–30.

S2(R1) I. Guidance on genotoxicity testing and data interoretation for pharmaceuticals intended for human use. 2011.

Prajapati JD, Kleinekathöfer U, Winterhalter M. How to Enter a Bacterium: Bacterial Porins and the Permeation of Antibiotics. Chem Rev. 2021;121(9):5158–92.

Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res. 1983;113(3–4):173–215.

Roantree RJ, Kuo TT, MacPhee DG. The effect of defined lipopolysaccharide core defects upon antibiotic resistances of Salmonella typhimurium. J Gen Microbiol. 1977;103(2):223–34.

Povirk LF, Austin MJ. Genotoxicity of bleomycin. Mutat Res. 1991;257(2):127–43.

Doerr CL, Harrington-Brock K, Moore MM. Micronucleus, chromosome aberration, and small-colony TK mutant analysis to quantitate chromosomal damage in L5178Y mouse lymphoma cells. Mutat Res. 1989;222(3):191–203.

Hecht SM. Bleomycin: new perspectives on the mechanism of action. J Nat Prod. 2000;63(1):158–68.

Chen J, Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer. 2005;5(2):102–12.

Umezawa K, Haresaku M, Muramatsu M, Matsushima T. Mutagenicity of anthracycline glycosides and bleomycins in Salmonella assay system. Biomed Pharmacother. 1987;41(5):214–8.

M7(R2) I. Assessment and control of DNA reactive (mutagenic) impurities in phermaceuticals to limit potential carcinogenic risk. 2023.

Nomura K, Hashimoto S, Takeyama R, Tamiya M, Kato T, Muraoka T, et al. Broadly Applicable and Comprehensive Synthetic Method for N-Alkyl-Rich Drug-like Cyclic Peptides. J Med Chem. 2022;65(19):13401–12.

Thông tin
Thông tin xuất bản

Genes and Environment

Tập 45 Số 1

Thông tin tác giả